Hanif is the founder and CEO of Sinophi Healthcare, a company which invests in and manages hospitals in China, focusing on public general hospitals and selected specialty hospitals. Sinophi works in partnership with hospitals in China’s rapidly growing urban areas to deliver improvements in the delivery of healthcare. Sinophi brings to hospitals in China international hospital expertise and technology, and builds partnerships with leading UK and international healthcare service and product partners. Earlier in his career, Hanif qualified as a doctor and practiced in the UK. He then spent eleven years in investment banking in corporate finance, derivatives and asset management with financial institutions including Prudential-Bache in London and New York, and Société Générale (SocGen) in Paris and Hong Kong. Returning to healthcare in 2000, Hanif undertook (as COO for Hong Kong) the restructuring of then HK-listed ehealthcareasia.com which he turned from loss to profit in nine months. This included the development of an innovative, web-based, combined medical claims processing and clinic management software and its implementation to Hong Kong’s largest physician group of over 700 doctors. Hanif graduated in medicine from Cambridge University and received his MBA from The Wharton School, USA.
David Faulkner is a Managing Director of Colliers International responsible for valuation and advisory services in the Asian region. He joined Colliers International in 2003 after 15 years with Insignia Brooke, and has been based in Asia for over 30 years. He has advised on a variety of major projects in Hong Kong, China and elsewhere in the Asian region including valuations, feasibility studies, development consultancy and structuring investments. He covers all the major sectors including residential, commercial, retail, industrial, hospitality and leisure. He also acts as an independent expert in making determinations in commercial rent disputes and has advised on a number of complex property valuation issues. David currently chairs Colliers International’s global valuation group and is actively involved in valuation assignments across the globe. David is a trustee of the International Property Measurement Standards Coalition, and is also a past member of International Valuation Professional Board of the International Valuation Standards Council (IVSC); a member of the Royal Institution of Chartered Surveyors (RICS) Global Valuation Professional Group Board; a trustee of the Urban Land Institute (ULI); practising member of The Academy of Experts and a member of the Best Practices Committee of the Asia Pacific Real Estate Association (APREA).
Thalia Georgiou is the Founder of Asia Care Group; a boutique healthcare advisory firm that supports clients to improve the efficiency and effectiveness of healthcare. Previously, Thalia held a number of senior healthcare management roles in both the UK and Asia, including leading KPMG’s healthcare practice in Hong Kong and Heading the Public Health Office for London. Thalia was recently named as one of the U.K’s "35 top business women under 35” by Management Today, for her substantial contribution to leading change in the health sector. Thalia set up her first healthcare consulting business aged just 26; which grew to serve an international clientele including the Governments of the UK, Hong Kong, Bermuda and Canada, as well as multinational clients. Her firm led several multi-million-pound projects, including the turnaround and restructuring of one of the UK’s largest hospital groups, the restructuring of London’s largest community provider and the development of the commercial strategy for establishing one of the five largest Immunology and Transplantation Centres in the world. Through her new firm, Thalia hopes to bring the same level of expertise to health systems across the Asia-Pacific region.
Jason Brockwell is an orthopaedic surgeon specialising in hip surgery. He is founder and medical director of asia medical specialists – a private specialist physician group serving Hong Kong, Macau, and China. With his experience of the local public and private medical systems and medical practice in Macau, Guangzhou, Shanghai & Beijing, he has a broad view of the issues affecting healthcare in Hong Kong and the region.
Karin has worked in the pharmaceutical, medical device & biotechnology industries for 20 years, of which the last 15 years were based in Asia (Shanghai, Hong Kong & Singapore). Karin has worked for MNC’s such as Eli Lilly, Fresenius Medical Care, Medtronic, Baxter & her professional experience ranges across various disciplines including Commercial Strategy, Regional (APAC) Marketing, M&A and Business Transformation. She is the co-founder of the Healthcare Drinks networking event (Hong Kong Chapter), which serves as a platform for all sectors of management in the healthcare industry to meet, exchange ideas and socialize. Her interests include mentoring healthcare start-ups & practicing yoga to maintain wellness.
Kennie Siu is the Regulatory Affairs Manager at Philip Morris Asia Limited (PMAL), an affiliate of Philip Morris International (PMI) who has made a commitment to replace cigarettes with innovative non-combustible products that have a potential to present less risk of harm to adult smokers. Kennie leads the government advocacy work for both Hong Kong and Macau, with the aim to be able to offer smokers, who would otherwise continue to smoke, a better alternative for themselves and their families around them. Kennie has more than 10 years’ experience in the UK and Asia Pacific region on government advocacy and regulatory affairs. She has previously held a Scientific Officer position in the Food Standards Agency (a non-ministerial government department of the Government of the UK). She has also worked with Kellogg’s, Starbucks and McDonald’s to direct both regional and market strategy in relation to Nutrition and food safety advocacy. She has obtained her Nutritionist profession in the UK and a Master degree in Toxicology from the University of Hong Kong. Empowered by the PMI’s vision, Kennie targets to bring the knowledge and expertise from the development of our reduced risk platform to contribute to the work and discussion in both the Healthcare and Smart Cites communities in BritCham. She advocates for a harm reduction approach for public health which could potentially accelerate the solutions for the healthcare problems in Hong Kong. She also believe the work on the reduced risk platform in PMAL plays a part in driving Hong Kong closer to the goal of a smarter living and smarter environment.
Xavier Lestrade is the Managing Director, Life Insurance AXA in Hong Kong and Macau. He is responsible for spearheading the company’s life insurance strategy definition and executing functions. Xavier is a member of the Executive Committee of AXA Hong Kong. A 20-year veteran of the company, Xavier brings with him nearly two decades of multi-market experience in the insurance industry and expertise spanning organisational strategy and governance, sales and distribution, product development, mergers and acquisitions and actuary. Prior to his present appointment, Xavier was with AXA Group based in France where he has accrued a wealth of global experience. He was most recently the Global Head of Distribution of AXA Group, a role he had held since 2009. Other senior positions he has held include Regional Head of Retail Distribution (2006-2009) and Head of Sales Performance Management Transformation for AXA France (2003-2006), Head of Products (Financial Planning and e-Learning) for AXA e-Services (2000-2002), M&A Project Manager for AXA Group (1997-2000), and Property & Casualty Actuary for AXA Canada (1995-1997). Xavier graduated from École Nationale Supérieure d’Arts et Métiers, an engineering school in France.
Alison joined HWB in March 2014, having previously worked as a partner with HWB's senior partner Chris Howse at Richards Butler in Hong Kong. She specialized in professional negligence and commercial litigation and has extensive experience in dispute resolution and commercial and professional negligence litigation. Alison returned to England in 1998 and was appointed as a Tribunal Judge with her Majesty's Courts and Tribunals Service specializing in Social Security law (including human rights and EC law, tax credits and benefit fraud). She was also appointed as a legally qualified chairperson for the Residential Property Tribunal in Wales, hearing appeals in respect of service charge disputes, enfranchisement valuations, determinations of fair and market rents, HMO licensing, rent repayment orders, park homes and local authority gypsy and traveller licensing issues and Right to Manage disputes. She continues to sit in both jurisdictions, returning to the UK for short periods to do so.
A medical doctor as well as a solicitor and solicitor advocate, David specialises in clinical negligence claims, advising healthcare professionals, including doctors, dentists, physiotherapists, midwives and nurses. His clients also include insurance companies, pharmaceutical companies, biotechnology companies, medical device manufacturers, hospitals, specialist group practices and other corporate healthcare providers. David’s legal career began with Richards Butler Hong Kong. He has experience in handling coroner's inquests, disciplinary and medical criminal proceedings, investigations commenced by the ICAC and Privacy Commissioners, product liability claims and other healthcare regulatory matters. David also has a special interest in providing advice on mental health laws and ethical issues such as consent and euthanasia. A proponent of alternative dispute resolution, David is an accredited mediator of the Hong Kong International Arbitration Centre. Before qualifying as a lawyer, David practised medicine for five years in the UK. He remains a CME-certified medical practitioner and in 2008 was appointed an Honorary Associate Professor of the University of Hong Kong Li Ka Shing Faculty of Medicine. Between 1991 and 1996, David practised general medicine as a house physician and then as a general surgeon. He subsequently worked in private medical practice in the UK as a part-time resident medical officer in various hospitals. He has been registered as a medical practitioner in the UK since 1991 and in Hong Kong since 1994. In 2016 David was granted Higher Rights of Audience and accredited as a Solicitor Advocate by the Higher Rights Assessment Board in Hong Kong. David is accredited in the civil proceedings category, by way of assessment. David has substantial advocacy experience representing clients before the Coroner's court and at Medical and Dental Council hearings. As a Solicitor Advocate David may also advocate for clients, similar to a barrister, in Hong Kong's Court of First Instance, Court of Appeal and Court of Final Appeal.
Frances Moffett-Kouadio is the Trade Commissioner to Hong Kong & Macao. She joined DTI (now the Department for Business, Innovation and Skills-BIS) as a fast-streamer in 2001, following a successful teaching career. At DTI she led on an EU Directive, wrote the Departments first Equality Impact Assessment and worked on the Business Support transformation programme, before joining UK Trade & Investment in 2004. Frances has a range of experience in different markets, including Iraq, India, Pakistan, Sri Lanka, Bangladesh, South Africa and was Director of Trade & Investment at the British Embassy in Abu Dhabi for the five years prior to taking up the role of Trade Commissioner in Hong Kong.
Cherry is based in Hong Kong and with 15 years of experience in management consulting in the area of Operational Due Diligence, Divestiture and Separation Management, Post Deal Merger Integration planning and execution in pharmaceutical and retail industries.
Tiffany Lam is the Senior External Affairs Manager of GlaxoSmithKline Limited, a global science-led healthcare company with business focusing on medicines, vaccines and consumer healthcare products. Our local focus is ensuring local people have timely access to our products to help them do more, feel better and live longer. Tiffany has over 12 years of experience in pharmaceutical industry for various functions ranging from sales, marketing, medical affairs to external affairs. She joined the BPU since 2013 and the healthcare committee which was set up this year. Recently, she also took the lead for primary care taskforce for the Hong Kong Association of Pharmaceutical Industry.
Tracy is a partner at Baker & McKenzie's Hong Kong office and is the co-head of the Healthcare Industry Group in China and Hong Kong. She is experienced in M&A as well as corporate and commercial matters relating to investment in China, and regularly acts for clients in complex cross-border transactions. Tracy is acknowledged as a leading lawyer in her field by various legal publications including Chambers Global, Chambers Asia and IFLR1000.
Dr. Isabella Liu is a partner at Baker & McKenzie's Hong Kong office. Isabella has extensive experience in advising clients in the Healthcare industry in a broad range of IP and regulatory issues in China and Hong Kong, including patent protection, IP licensing, administrative and civil enforcement of soft IP rights as well as regulatory issues relating to clinical studies, market entry and distribution of healthcare products. She is the honorary legal advisor to the Hong Kong Association of the Pharmaceutical Industry. Isabella was recently recognized as Intellectual Property: Trademarks Lawyer of the Year (Hong Kong) by International Law Office (ILO) Client Choice Award (2016), and recommended as a leading lawyer by IAM Patent 1000 and Chambers Asia.